BTVPUR (bluetongue-virus serotype-1 antigen...) – Summary of product characteristics - QI04AA02

Updated on site: 21-Sep-2017

Medikamentets navn: BTVPUR
ATC: QI04AA02
Stoff: bluetongue-virus serotype-1 antigen /bluetongue-virus serotype-8 antigen
Produsent: Merial

1.NAME OF THE VETERINARY MEDICINAL PRODUCT

BTVPUR suspension for injection for sheep and cattle.

2.QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 1 ml contains:

Active substances *:

Inactivated Bluetongue Virus .........................................strain specific pass level (log10 pixels) **

(*) maximum of two different inactivated bluetongue virus serotypes

(**)Strain-specific

(**) Antigen content (VP2

pass levels

protein) by immuno-assay

BTV1

1.9 log10 pixels/mL

BTV4

1.86 log10 pixels/mL

BTV8

2.12 log10 pixels/mL

A confirmatory final potency test by seroneutralisation in rats is conducted when a batch is released

Adjuvants:

 

Al3+ (as hydroxide)

2.7 mg

Saponin

30 HU**

(**) Haemolytic units

 

For the full list of excipients, see section 6.1.

The type of strain(s) (two strains at most) included in the final product will be selected based on the epidemiological situation at the time of manufacturing and will be stated on the package and in the package leaflet

3.PHARMACEUTICAL FORM

Homogeneous milky white suspension for injection.

4.CLINICAL PARTICULARS

4.1Target species

Sheep and cattle

4.2Indications for use, specifying the target species

Active immunisation of sheep and cattle to prevent viraemia* and to reduce clinical signs caused by bluetongue virus serotypes 1, 4 and/or 8 (combination of maximum 2 serotypes)

*(below the level of detection by the validated RT-PCR method at 3.68 log10 RNA copies/ml, indicating no infectious virus transmission)

Onset of immunity has been demonstrated 3 weeks after the primary vaccination course. The duration of immunity for cattle and sheep is 1 year after primary vaccination course.

4.3Contraindications

None.

4.4Special warnings for each target species

If used in other domestic and wild ruminant species that are considered at risk of infection, its use in these species should be undertaken with care and it is advisable to test the vaccine on a small number of animals prior to mass vaccination. The level of efficacy for other species may differ from that observed in sheep and cattle.

4.5Special precautions for use

Special precautions for use in animals

Vaccinate healthy animals only.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

None

4.6Adverse reactions (frequency and seriousness)

In very rare cases it has been observed a small local swelling at the injection site (at most 32 cm² in cattle and 24 cm2 in sheep) which becomes residual 35 days later (≤ 1 cm2).

In very rare cases it has been observed a transient increase in body temperature, normally not exceeding an average of 1.1 °C, may occur within 24 hours after vaccination.

The frequency of adverse reactions is defined using the following convention:

-Very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment).

-Common (more than 1 but less than 10 animals in 100 animals).

-Uncommon (more than 1 but less than 10 animals in 1,000 animals).

-Rare (more than 1 but less than 10 animals in 10,000 animals).

-Very rare (less than 1 animal in 10,000 animals, including isolated reports).

4.7Use during pregnancy, lactation or lay

Can be used during pregnancy and lactation

The safety and the efficacy of the vaccine have not been established in breeding males. In this category of animals the vaccine should be used only according to the benefit/risk assessment by the responsible veterinarian and/ or national Competent Authorities on the current vaccination policies against Bluetongue Virus (BTV).

4.8Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

4.9Amounts to be administered and administration route

Apply usual aseptic procedures.

Shake gently immediately before use. Avoid bubble formation, as this can be irritating at the site of injection. The entire content of the bottle should be used immediately after broaching and during the same procedure. Avoid multiple vial broaching.

Administer one dose of 1 ml subcutaneously according to the following vaccination scheme:

Primary vaccination

In sheep

-First injection: from 1 month of age in naive animals (or from 2.5 months of age in young animals born to immune sheep).

-Second injection: after 3-4 weeks

For a monovalent vaccine containing an inactivated Bluetongue Virus serotype 4, one injection is sufficient.

In cattle

-First injection: from 1 month of age in naive animals (or from 2.5 months of age in young animals born to immune cattle).

-Second injection: after 3-4 weeks

Revaccination

Annual.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Very rare and transient apathy can be observed after the administration of a double-dose of the vaccine. No other adverse reactions except those mentioned in section 4.6 were observed.

4.11 Withdrawal period

Zero days.

5.IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: bluetongue virus vaccine, ATC vet code QI04AA02 (sheep) and QI02AA08 (cattle).

The vaccine contains inactivated Bluetongue Virus with aluminium hydroxide and saponin adjuvants. It induces an active and specific immunity against bluetongue virus in the vaccinated animal.

6.PHARMACEUTICAL PARTICULARS

6.1List of excipients

Silicon antifoam

Phosphate buffer

Glycine buffer

Aluminium hydroxide

Saponin

6.2Incompatibilities

Do not mix with any other veterinary medicinal product.

6.3Shelf life

Shelf life of monovalent or bivalent formulation with Bluetongue Virus serotypes 1 and/or 8 (100 ml, 50 ml and 10 ml bottles): 2 years

Shelf life of monovalent or bivalent formulation with Bluetongue Virus serotype 4 (100 ml, 50ml and 10 ml bottles): 18 months

Shelf life after first opening the immediate packaging: use immediately.

6.4Special precautions for storage

Store and transport refrigerated (2 °C – 8 °C)

Do not freeze

Protect from light

6.5Nature and composition of immediate packaging

Polypropylene bottle of 50 or 100 ml with butyl elastomer closure.

Box of 1 bottle of 100 doses (1 x 100 ml)

Box of 10 bottles of 100 doses (10 x 100 ml)

Box of 1 bottle of 50 doses (1 x 50 ml)

Box of 10 bottles of 50 doses (10 x 50 ml)

Type I glass bottle of 10 ml with butyl elastomer closure.

Box of 1 bottle of 10 doses (1 x 10 ml)

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7.MARKETING AUTHORISATION HOLDER

MERIAL

29, avenue Tony Garnier 69007 Lyon

FRANCE

8.MARKETING AUTHORISATION NUMBER(S)

EU/2/10/113/001-030

9.DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 17/12/2010

Date of latest renewal: 08/09/2015

10.DATE OF REVISION OF THE TEXT

Detailed information of this product is available on the website of the European Medicines Agency http://www.ema.europa.eu.

PROHIBITION OF SALE, SUPPLY AND/OR USE

The manufacture import, possession, sale, supply and/or use of BTVPUR containing serotypes 1,

4 and 8 may be prohibited in a certain Member State on the whole or part of their territory pursuant to national legislation. Any person intending to manufacture, import, possess, sell, supply and/or use BTVPUR must consult the relevant Member State’s competent authority on the current vaccination policies prior to the manufacture, import, possession, sale, supply and/or use.

Kommentarer